Internal Medicine, Hematology & Oncology · Pembroke Pines, FL
NPI
1447492913
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
603 N Flamingo Rd Ste 151
Pembroke Pines, FL, 33028
Phone (954) 265-4325
Groups this clinician bills Medicare through
Medicare paid, 2024
$47K
550 services
Medicare patients, 2024
138
Average age 74
Drug cost, 2024
$5.6M
634 prescriptions
Company payments, 2025
$2,868
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yehuda E Deutsch was code 99214 (office e&m - established), 170 times for 68 patients. In total Yehuda E Deutsch billed 550 services in 15 codes, and Medicare paid $47K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 170 | 68 | $75.82 | $13K |
| 99233 Hospital E&M - Subsequent | Facility | 117 | 26 | $95.36 | $11K |
| 99215 Office E&M - Established | Facility | 91 | 44 | $110.93 | $10K |
| 99214 Office E&M - Established | Office | 62 | 33 | $62.52 | $3,876 |
| 99215 Office E&M - Established | Office | 28 | 24 | $92.61 | $2,593 |
| 99222 Hospital E&M - Initial | Facility | 16 | 16 | $105.71 | $1,691 |
| 99213 Office E&M - Established | Office | 12 | 11 | $51.95 | $623 |
By year: 2022 $55K for 665 services; 2023 $41K for 529 services; 2024 $47K for 550 services.
Medicare prescription drug claims, 2024
In 2024, the drug Yehuda E Deutsch prescribed most often to Medicare patients was Acyclovir, with 66 prescriptions and refills. In total Yehuda E Deutsch wrote 634 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 66 | 104 | 17 | $946 |
| Iclusig Ponatinib Hcl | 62 | 62 | Under 11 | $1.3M |
| Imbruvica Ibrutinib | 43 | 48 | Under 11 | $802K |
| Revlimid Lenalidomide | 41 | 41 | Under 11 | $661K |
| Jakafi Ruxolitinib Phosphate | 34 | 34 | Under 11 | $519K |
| Venclexta Venetoclax | 30 | 30 | 11 | $186K |
| Inqovi Decitabine/Cedazuridine | 29 | 29 | Under 11 | $231K |
| Brukinsa Zanubrutinib | 24 | 24 | Under 11 | $349K |
| Prednisone Generic | 24 | 24 | Under 11 | $62.44 |
| Imatinib Mesylate Generic | 19 | 19 | Under 11 | $12K |
| Sprycel Dasatinib | 16 | 16 | Under 11 | $236K |
| Posaconazole Generic | 16 | 16 | Under 11 | $15K |
| Ojjaara Momelotinib Dihydrochloride | 16 | 16 | Under 11 | $424K |
| Hydroxyurea Generic | 15 | 37 | Under 11 | $376 |
| Pregabalin Generic | 15 | 15 | Under 11 | $90.99 |
Brand drugs: 356 claims; generic drugs: 278 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Yehuda E Deutsch $2,868 ($2,868 in general payments such as food, travel and fees) from 9 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,788.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.